General Counsel Profile: Bristol-Myers Squibb Co.

General Counsel Sandra Leung discusses the legal ramifications of Bristol-Myers Squibb's transformation into a "next-generation biopharmaceutical company."

This article requires premium access

This article requires free registration to The National Law Journal. Please sign in or register to read the full text.